US Anti-Migraine Drugs Market to Exceed $3.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a US and European report on Anti-Migraine Drugs. The US and European markets for anti-migraine drugs are projected to exceed $3.2 billion and $734 million, respectively, by 2015. There are a large number of drugs, both preventive and abortive, available in the US and European markets, but the number of those using these medicines are not as many as those suffering from this temporarily disabling condition.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Anti-Migraine Drugs: A US and European Market Report

San Jose, California (PRWEB) February 22, 2010

Migraine, a potentially serious neurological disorder, is characterized by recurrent attacks of headache that vary widely in frequency, severity and duration. Migraine sufferers generally experience a throbbing/ pulsating pain on one side of their head, which is accompanied with dizziness, vomiting, nausea, and sensitivity to sound/ light, while other symptoms may also co-exist. A migraine attack may last for several hours or extend up to a day or more and can recur many times a week.

The US represents the largest market worldwide for anti-migraine drugs, as stated by the new market research report on anti-migraine drugs. The US market is large and competitive with several prescription-only and non-prescription medicines available for the treatment of migraine headaches. Abortive or acute medicines are widely prescribed to migraine patients, and among these medicines, Triptans are the most prescribed drugs. Though there is a declining sales trend, it might be reversed or at least counterbalanced, based on the approval of new potential therapies such as Merck's Telcagepant and MAP Pharmaceuticals' Levadex, both currently in Phase III clinical developments.

Also helping the market to become optimistic could be the recently approved drug-device combination, Sumavelâ„¢ DoseProâ„¢, from the stable of Zogenix. Sumavel DosePro is a needle-free delivery system indicated for the treatment of migraine with aura or migraine without aura as well as cluster headache. The sumatriptan injection is clinically proven to provide rapid action, and any take up in prescription of this drug would help lift prospects of the US anti-migraine drugs market.

Key players profiled in the report include Abbott Laboratories Inc., Eisai Inc., Eli Lilly and Company, Johnson & Johnson Inc., Kowa Pharmaceuticals America, Inc., MAP Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., Pozen, Roxro Pharma, Inc., Winston Pharmaceuticals, Inc., Wyeth Consumer Healthcare, Zogenix Inc., AstraZeneca Plc, Bayer AG, Ethypharm S.A., GlaxoSmithKline Plc, Meda AB, UCB S.A., among others.

The report titled "Anti-Migraine Drugs: A US and European Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market, clinical pipeline, product approvals, product introductions, and recent industry activity. The study analyzes market data and analytics in terms of value sales for the United States and Europe.

For more details about this comprehensive market research report, please visit -
http://www.strategyr.com/Anti_Migraine_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

###


Contact

Attachments

Press Release Attachment

Global Industry Analysts, Inc.